wjpls, 2025, Vol. 11, Issue 2, 324-341 *Review Article* ISSN 2454-2229

World Journal of Pharmaceutical and Life Sciences
WJPLS
www.wjpls.org
SJIF Impact Factor: 7.409

THE TRANSITION ELEMENTS AND INNER TRANSITION ELEMENTS: THE NEW PROSPECT TO FOCUS ON PHARMACEUTICAL MEDICATIONS

[1*]Dr. Dhrubo Jyoti Sen, [2]Dr. Pruthviraj K. Chaudhary, [3]Dr. Dhaval Patel and [4]Dushyant P. Chaudhary

[1]School of Pharmacy, Techno India University, Salt Lake City, Sector-V, EM: 4/1, Kolkata-700091, West Bengal, India.
[2]Shri Sarvajanik Pharmacy College, Gujarat Technological University, Arvind Baug, Mehsana-384001, Gujarat, India.
[3]Jamp India Pharmaceutical Pvt. Ltd, Office No. A - 1207, 12th Floor, Navratna Corporate Park, Ambli – Bopal Road, Ambli, Ahmedabad, Gujarat-380058, India.
[4]The University of Texas at Arlington, 701 South Nedderman Drive, Arlington, Texas-76019, USA.

***Corresponding Author: Dr. Dhrubo Jyoti Sen**

School of Pharmacy, Techno India University, Salt Lake City, Sector-V, EM: 4/1, Kolkata-700091, West Bengal, India.

Article Received on 06/01/2025 **Article Revised on 26/01/2025** **Article Accepted on 15/02/2025**

ABSTRACT

D and f block elements, known for their unique chemical properties; play a pivotal role in pharmaceutical medication preparation. These elements, which include transition metals from the d block and inner transition metals from the f block, are integral to drug design, particularly due to their ability to form stable complexes with organic molecules. Transition metals, such as iron, zinc, and copper, are essential in enzyme catalysis, cellular functions, and as cofactors in biological processes, making them crucial for drug development. Notably, platinum-based chemotherapy agents, such as cisplatin, have revolutionized cancer treatment by targeting DNA within cancer cells. Additionally, metals like silver and copper are utilized in the development of antimicrobial agents, contributing to the fight against resistant pathogens. F block elements, including lanthanides and actinides, also find use in medicine, particularly in diagnostic imaging and radiopharmaceuticals. For instance, gadolinium is widely employed in MRI contrast agents due to its magnetic properties. The use of radioactive isotopes of actinides, such as radium, in cancer therapies further highlights the importance of these metals in modern medicine. However, the use of d and f block elements in pharmaceuticals presents challenges, including toxicity concerns and issues related to bioavailability and pharmacokinetics. As such, ongoing research focuses on optimizing the therapeutic potential of these metals while minimizing side effects. The future of metal-based drugs lies in personalized medicine, targeted drug delivery systems, and innovations in nanotechnology, promising more efficient and safe treatments. This review explores the diverse applications of d and f block elements in pharmaceutical preparations and the future directions in this field.

KEYWORDS: D block elements, f block elements, Electronic configuration, AUFBAU principle, s, p ,d, f subshell, Transition metals, Metalloenzymes, Platinum-based drugs, Antimicrobial agents, Radiopharmaceuticals, Metal complexes, Drug delivery systems, Toxicity and bioavailability.

INTRODUCTION

D and f block elements are two groups of elements in the periodic table that are crucial to various chemical and biological processes, including pharmaceutical applications. In chemistry, a transition metal (or transition element) is a chemical element in the d-block of the periodic table (groups 3 to 12), though the elements of group 12 (and less often group 3) are sometimes excluded. The lanthanide and actinide elements (the f-block) are called inner transition metals and are sometimes considered to be transition metals as well. Inner transition metals (ITM) are chemical elements on the periodic table. They are normally shown in two rows below all the other elements. They include elements 57-71, or lanthanides, and 89-103, or actinides. The lanthanides are very similar, and the actinides are all radioactive.

D Block Elements (Transition Metals)

The d block elements are the elements found in groups 3 to 12 of the periodic table. These elements are characterized by having their valence electrons in the d orbital, which allows them to form multiple oxidation states and coordination complexes. This flexibility makes transition metals essential in catalysis, industrial processes, and biological functions. Key properties of d block elements include:

Variable Oxidation States: Transition metals can exhibit multiple oxidation states, which enables them to participate in a wide variety of chemical reactions, including those involved in drug mechanisms.

Coordination Chemistry: Transition metals can form stable complexes with ligands, making them ideal candidates for drugs that require interaction with biomolecules like enzymes or DNA.[1]

Metal-Protein Interactions: These metals often act as cofactors in enzymes and other proteins, which are integral to biological processes such as metabolism, oxygen transport (e.g., iron in haemoglobin), and immune function (e.g., zinc in immune cells).

Examples of important d block elements in pharmaceutical applications include iron, copper, zinc, and platinum. These metals are used in a range of drug formulations, including anticancer drugs (e.g., platinum-based drugs like cisplatin), antibiotics, and enzyme inhibitors.

F Block Elements (Lanthanides and Actinides)

The f block elements are located in two rows below the main body of the periodic table: the lanthanides (rare earth elements) and the actinides (which include radioactive elements). These elements have electrons filling their f orbitals and are generally known for their magnetic, fluorescent, and radioactive properties.

Lanthanides: The lanthanides are typically used in medicinal imaging and diagnostics, as they have unique electronic and magnetic properties. For instance, gadolinium is commonly used in MRI contrast agents due to its ability to enhance magnetic resonance imaging.

Actinides: Many of the actinides, particularly uranium and radium, are radioactive and have applications in cancer therapy (radiopharmaceuticals) due to their ability to emit radiation that can target and destroy cancer cells.[2]

Despite their promising therapeutic applications, the f block elements also pose challenges, such as toxicity and handling difficulties, especially with radioactive isotopes. However, their unique properties, such as their role in imaging or targeted radiation therapy, make them indispensable in the pharmaceutical field.

The d and f block elements, which include transition metals and inner transition metals, have long been recognized for their importance in various aspects of pharmaceutical development and therapy. Their unique chemical properties—such as variable oxidation states, coordination chemistry, and catalytic abilities—make them indispensable in the preparation of drugs, diagnostic tools, and therapeutic agents. These elements have evolved from being simple metals with limited use in medicine to becoming central components in life-saving treatments and diagnostic techniques.



Figure 1: Shell, subshell and orbital with AUFBAU principle.

Historical Context of Their Use in Medicine

Historically, the use of metals in medicine dates back to ancient civilizations. However, it was not until the 20th century that the therapeutic potential of d and f block elements was fully recognized. The development of platinum-based chemotherapy drugs in the 1970s marked a significant milestone in the use of transition metals in medicine. Cisplatin, a platinum-based compound, became one of the first effective chemotherapy agents for treating various types of cancer. This breakthrough demonstrated the potential of transition metals to interact with biological systems, particularly in the context of cancer treatment, where they could target and disrupt the DNA of cancerous cells.[3]

Following the success of cisplatin, other d block metals, such as gold, copper, and iron, were investigated for their roles in drug design, leading to the development of anti-inflammatory and antimicrobial therapies. Gold, for example, was used in the treatment of rheumatoid arthritis, particularly in the form of gold salts, which were found to reduce inflammation and immune response. The discovery of these therapeutic benefits laid the foundation for the continued exploration of transition metals in medicine.

The inner transition metals, particularly lanthanides and actinides, also began to see pharmaceutical applications, primarily due to their unique properties in diagnostic imaging and radiotherapy. Lanthanides, such as gadolinium, became widely used as contrast agents in magnetic resonance imaging (MRI) due to their ability to alter the magnetic properties of tissues, thereby enhancing image quality.[4]

Roles in Drug Development and Therapy

The d and f block elements play a central role in drug development and therapeutic interventions. The most prominent example is the use of platinum-based compounds in chemotherapy. Cisplatin, carboplatin, and oxaliplatin have become cornerstone drugs in the treatment of cancers such as ovarian, testicular, and lung cancer. These drugs work by forming highly reactive platinum-DNA adducts which interfere with DNA replication and induce cell death in rapidly dividing cancer cells. Their effectiveness has spurred research into the development of additional metal-based chemotherapeutic agents, with modifications to enhance efficacy and reduce side effects.[5]

In addition to anticancer therapy, transition metals are also integral in the development of antimicrobial agents. Metals such as silver and copper have long been known for their antimicrobial properties. Silver, in particular, has been used for centuries in wound care, as it is effective against a broad spectrum of bacteria. In modern medicine, silver nanoparticles are used in wound dressings, catheters, and medical devices to prevent infections. Copper has similarly been incorporated into antimicrobial coatings for surfaces and textiles, reducing the spread of infections in healthcare settings.

The role of metals in enzyme catalysis is another critical area where transition metals influence pharmaceutical development. Metals such as zinc, cobalt, and magnesium are often found as cofactors in enzymes, and their interaction with biomolecules is essential for maintaining biological processes. Zinc, for instance, is vital in the structure and function of enzymes involved in immune response, DNA repair, and cellular metabolism. As such, zinc supplementation is commonly used to treat immune deficiencies and support wound healing.[6]

Lanthanides and actinides, though less common in therapeutic use, are invaluable in the field of diagnostics and radiopharmaceuticals. Gadolinium, a lanthanide element, is widely used in MRI contrast agents due to its high magnetic moment, which enhances the imaging capabilities of MRI scans. In addition, radioactive isotopes of actinides, such as radium and thorium, have found applications in cancer treatment, particularly in targeted radiotherapy, where their radioactivity is used to selectively destroy tumour cells.

General Properties of d and f Block Elements

The d and f block elements, which include transition metals and inner transition metals, exhibit unique properties that are crucial to their chemical behaviour and applications in various fields, including pharmaceuticals. Their ability to form coordination compounds, their variable oxidation states, and their involvement in catalytic processes are largely influenced by their electronic configuration. Understanding these properties allows for a deeper insight into their roles in drug binding and biological interactions.[7]

Electronic Configuration of d and f Block Elements

The electronic configuration of transition metals in the d block and inner transition metals in the f block is one of the key factors that influence their chemical behaviour. Transition metals have their outermost electrons filling the d orbitals, while inner transition metals (lanthanides and actinides) fill the f orbitals.

The d Block Elements (Transition Metals): Transition metals are characterized by their incompletely filled d subshells, which leads to their ability to exist in multiple oxidation states. For example, iron (Fe) can exist in both +2 and +3 oxidation states (Fe^{2+} and Fe^{3+}), while copper (Cu) can exist as Cu^{+} and Cu^{2+}. This variability in oxidation states allows transition metals to participate in a wide range of chemical reactions, making them highly versatile in biological systems and industrial applications.[8]

The f Block Elements (Lanthanides and Actinides): The f block elements have electrons filling their f orbitals, which are generally shielded from external interactions, making these elements less reactive than their d block counterparts. The lanthanides (rare earth elements) are often trivalent (e.g., La^{3+}, Ce^{3+}), while actinides can exist in multiple oxidation states due to their complex electron arrangements. These metals are important in applications such as radiopharmaceuticals and MRI contrast agents.

Influence of Electronic Configuration on Chemical Behaviour

The unique electronic configuration of d and f block elements greatly influences their chemical reactivity.

Variable Oxidation States: The ability of transition metals to exhibit multiple oxidation states is a result of the relatively small energy differences between their (n-1)d and ns orbitals. This allows for the reversible loss or gain of electrons, a property essential for catalytic cycles, enzyme activity, and drug interactions. For example, cobalt in the +2-oxidation state (Co^{2+}) and the +3-oxidation state (Co^{3+}) plays a significant role in the activity of cobalt-based enzymes, as well as in the formulation of certain anticancer drugs.[9]

Ligand Binding and Coordination Chemistry: The d and f block elements can form stable complexes with ligands, which are molecules or ions that donate electron pairs to the metal center. This ability to form coordination compounds is a defining characteristic of transition and inner transition metals. The coordination number (the number of ligands attached to the metal ion) and the geometry (the arrangement of ligands around the metal) are determined by the electronic configuration of the metal.

Coordination Compounds and Their Relevance to Drug Binding

Coordination compounds are vital in pharmaceutical chemistry due to their ability to bind to biological molecules and interact with enzymes, proteins, and DNA. The formation of such complexes is central to the therapeutic action of many metal-based drugs.

Coordination Compounds in Drug Binding: Transition metals can form coordination complexes with organic molecules, including drugs. For example, cisplatin, a platinum-based chemotherapy drug, binds to DNA via the platinum atom, forming coordination bonds with the nitrogen atoms of purine bases. This interaction disrupts DNA replication and triggers apoptosis (programmed cell death) in cancer cells. Similarly, iron forms coordination complexes with heme, a prosthetic group in haemoglobin, allowing for the reversible binding of oxygen in the blood.[10]

Ligands in Metal-Based Drugs: The ligands in these complexes can be small molecules such as chloride ions (as in the case of cisplatin), or larger organic molecules like proteins and peptides. The strength and nature of the bonds formed between the metal and the ligands influence the stability and reactivity of the complex, which in turn determines its pharmacological properties. Copper, for instance, is involved in the catalysis of various enzymatic reactions as part of copper-containing enzymes (e.g., cytochrome c oxidase), and its coordination with ligands in enzyme active sites is crucial for its biological function.

Drug Delivery Systems: The coordination chemistry of transition metals also enables their use in targeted drug delivery systems. By attaching therapeutic agents to metal ions, it is possible to design drugs that are selectively delivered to specific tissues or cells. This is particularly useful in cancer treatment, where metal complexes can be engineered to target tumour cells, thus improving the efficacy and reducing the toxicity of the drug.

Biological Availability and Toxicity Concerns of d and f Block Elements in Pharmaceutical Medication Preparation

The d and f block elements are essential in the pharmaceutical industry due to their unique properties, such as the ability to form coordination compounds and exhibit multiple oxidation states, which make them ideal candidates for therapeutic applications. However, while these elements have significant potential for drug development, their biological availability and toxicity remain critical concerns in pharmaceutical formulation. These factors must be carefully managed to ensure the safety and efficacy of metal-based drugs.[11]

Role of Bioavailability in Pharmaceutical Development

Bioavailability refers to the extent and rate at which the active ingredient or therapeutic agent in a drug reaches its site of action in the body. For metal-based drugs, bioavailability is influenced by several factors, including the metal's solubility, the nature of the coordination complex, and its ability to interact with biological molecules.

Solubility: Many d and f block metal compounds must be sufficiently soluble in the bloodstream to be absorbed effectively. For instance, platinum-based drugs like cisplatin are administered intravenously because they do not dissolve well in water, and direct injection ensures they reach their target tissue, such as cancer cells. The solubility of these compounds is often enhanced through modifications, such as the use of ligands that increase the drug's stability and solubility.

Transport to Target Sites: Once absorbed, metal ions or complexes must be able to navigate biological membranes to reach their target site. Transition metals like iron are naturally involved in biological processes, such as oxygen transport in haemoglobin, because of their inherent bioavailability and interaction with proteins and enzymes. Similarly, metal-based drugs must be designed to interact specifically with their target biomolecules, such as DNA or enzymes, to be effective.[12]

Drug Formulation: To optimize bioavailability, pharmaceutical formulations may include carriers or ligands that improve the stability and absorption of metal-based drugs. For example, the use of liposomes, nanoparticles, or chelating agents can help to enhance the solubility and targeted delivery of metal complexes, increasing their bioavailability and reducing side effects.

Toxicity Concerns in Metal-Based Drugs

While d and f block elements are invaluable in medicine, their toxicity remains a significant concern. The toxicity of metal-based drugs is often linked to the metal's reactivity, its ability to accumulate in tissues, and its potential to interfere with essential biological processes.

Platinum-Based Drugs: Platinum compounds such as cisplatin are among the most widely used metal-based drugs, especially in cancer treatment. However, these drugs can exhibit significant toxicity, particularly in organs such as the kidneys, liver, and nervous system. Cisplatin, for example, can cause nephrotoxicity by interacting with kidney cells, leading to kidney damage and dysfunction. To mitigate these side effects, newer platinum-based drugs (e.g., carboplatin and oxaliplatin) have been developed, which are less toxic but still effective in treating cancer.

Accumulation and Long-Term Effects: One of the main concerns with metal toxicity is the potential for accumulation in tissues over time. Elements like copper and iron can accumulate in the body if not properly regulated, leading to conditions such as Wilson's disease (copper toxicity) or hemochromatosis (iron overload). Similarly, radioactive metals like radium can accumulate in bones and tissues, leading to long-term health risks, including cancer.

Reactivity and Cellular Damage: The high reactivity of certain transition metals can lead to cellular damage. For instance, platinum compounds form covalent bonds with cellular DNA, causing DNA cross-linking, which disrupts replication and leads to cell death. While this mechanism is useful in cancer therapy, it can also affect healthy cells, causing side effects such as nausea, hair loss, and immune suppression.[13]

Balancing Bioavailability and Toxicity in Drug Development

In pharmaceutical development, balancing bioavailability and toxicity is a critical task when working with d and f block elements. While these metals are effective in treating various diseases, such as cancer, infections, and anemia, their potential toxicity must be minimized to ensure patient safety.

Targeted Drug Delivery: Advances in drug delivery systems, such as nanoparticles and liposomal formulations, allow for the controlled release of metal-based drugs, improving bioavailability while reducing systemic toxicity. Targeting specific tissues or cells, such as tumour cells in cancer therapy, is a promising approach that increases the therapeutic index of metal-based drugs, making them more effective with fewer side effects.

Chelation Therapy: In cases of metal toxicity, chelating agents can be used to bind excess metal ions and facilitate their excretion from the body. For instance, dimercaprol and EDTA (ethylenediaminetetraacetic acid) are used to treat heavy metal poisoning by forming stable complexes with toxic metals, such as lead or mercury, and preventing their accumulation in tissues.

Role of d Block Elements in Pharmaceutical Medication

The d block elements, also known as transition metals, play an indispensable role in pharmaceutical medication due to their unique chemical properties, such as the ability to exist in multiple oxidation states, form coordination compounds, and participate in catalytic reactions. These metals are crucial in drug design, enzyme catalysis, and the development of metalloenzyme-based therapies, where their presence directly influences the effectiveness and mechanism of action of many pharmaceutical agents.

Transition Metals in Drug Design

Transition metals, such as iron, copper, zinc, and manganese, are often incorporated into drugs due to their ability to interact with biological molecules, specifically enzymes and other biomolecules. These metals' ability to adopt various oxidation states allows them to participate in complex biochemical processes, such as oxidation, reduction, and electron transfer. This versatility makes them valuable components in the design of therapeutic agents that target specific biological pathways.[14]

One of the most common uses of transition metals in drug design is in the development of metal-based chemotherapeutic agents. For example, platinum-based drugs, like cisplatin, carboplatin, and oxaliplatin, have become cornerstones in cancer treatment. These platinum compounds bind to DNA, causing cross-links between the DNA strands and preventing replication in rapidly dividing cancer cells. This interference with DNA leads to cancer cell death, making platinum-based drugs highly effective in treating cancers like ovarian, testicular, and lung cancer.

Examples of Transition Metals and Their Role in Enzyme Catalysis

Transition metals play an essential role in enzyme catalysis, where they act as cofactors, enabling enzymes to carry out a variety of chemical reactions that are vital to biological systems. These metals are integral to the structure and function of metalloenzymes, enzymes that require a metal ion at their active site for proper activity. Transition metals like iron, copper, zinc, and manganese are involved in various enzyme-catalyzed processes, influencing important metabolic pathways and biological functions.

Iron ($_{26}Fe^{56}$: $1s^2 2s^2 2p^6 3s^2 3p^6 3d^6 4s^2$): Iron is a key component of heme-containing enzymes, such as haemoglobin and myoglobin, which are responsible for oxygen transport and storage in the body. Additionally, iron is involved in a number of important enzymes, such as cytochrome P450 enzymes, which are involved in drug metabolism. Iron's ability to exist in both the +2 and +3 oxidation states enables it to participate in redox reactions, facilitating the transfer of electrons in biochemical processes.[15]

Copper ($_{29}Cu^{63.5}$: $1s^2 2s^2 2p^6 3s^2 3p^6 4s^1 3d^{10}$): Copper is involved in several metalloenzymes, including cytochrome c oxidase, which is a critical enzyme in the electron transport chain, and superoxide dismutase (SOD), an enzyme that protects cells from oxidative damage by converting superoxide radicals into less harmful molecules. Copper is essential in various biochemical reactions involving the transfer of electrons and has been linked to several disease states, including

Wilson's disease, a genetic disorder that leads to copper buildup in tissues.

Zinc ($_{30}Zn^{65}$: $1s^2 2s^2 2p^6 3s^2 3p^6 3d^{10} 4s^2$): Zinc is one of the most widely distributed transition metals in enzymes and plays a crucial role in hundreds of biological processes. It is a cofactor for enzymes like carbonic anhydrase, which helps regulate the pH of body fluids, and alkaline phosphatase, which is involved in the hydrolysis of phosphate groups. Zinc is also essential for the activity of DNA polymerases and other enzymes involved in DNA replication and repair, making it essential for cell growth and division.

Manganese ($_{25}Mn^{55}$:$1s^2 2s^2 2p^6 3s^2 3p^6 4s^2 3d^5$): Manganese is involved in the action of enzymes such as manganese superoxide dismutase (MnSOD), which helps protect cells from oxidative stress. Manganese also plays a role in arginase, which is involved in the metabolism of arginine, an amino acid important for the production of nitric oxide.

Importance in Metalloenzymes and Their Relevance to Disease Treatment

Metalloenzymes, enzymes that contain a metal ion as part of their active site, are critical for the proper functioning of biological systems. These enzymes catalyze reactions that are essential for processes such as cellular respiration, DNA replication, and detoxification. Many metalloenzymes are involved in disease-related pathways, making them valuable targets for drug development.

Cancer Treatment: As mentioned earlier, transition metals like platinum have been incorporated into chemotherapy drugs due to their ability to interact with DNA and inhibit its replication in cancer cells. Cisplatin, for instance, has revolutionized the treatment of certain cancers by targeting DNA, making it a cornerstone in cancer chemotherapy.

Antioxidant defence: Enzymes like superoxide dismutase (SOD), which contains copper and zinc, play a vital role in protecting cells from oxidative stress. Oxidative stress is implicated in a variety of diseases, including neurodegenerative diseases (e.g., Alzheimer's and Parkinson's), cardiovascular diseases, and cancer. As a result, the development of drugs that target metalloenzymes involved in antioxidant defense is an area of active research, aiming to mitigate oxidative damage and improve health outcomes.

Infectious Diseases: Transition metals are involved in the action of many enzymes that pathogens rely on for survival. For example, zinc is essential for the activity of enzymes in bacterial replication, and drugs targeting zinc-binding sites are being explored to inhibit bacterial growth and combat infections.

Platinum-Based Anticancer Agents: Mechanism of Action and Therapeutic Efficacy

Platinum-based drugs, particularly cisplatin and carboplatin, are widely used in chemotherapy for the treatment of various cancers, including testicular, ovarian, lung, bladder, and head and neck cancers. These drugs belong to a class of chemotherapy agents known as alkylating agents, which interfere with DNA replication and repair mechanisms, ultimately leading to cancer cell death.[16]

Mechanism of Action

The primary mechanism by which platinum-based drugs exert their anticancer effects involves the interaction with DNA. Cisplatin (cis-diamminedichloroplatinum (II)) and carboplatin (a derivative of cisplatin with a modified structure) are both platinum-containing compounds. After administration, these drugs are taken up by cancer cells through copper transporter proteins. Once inside the cell, cisplatin undergoes hydrolysis, where the chloride ions are replaced by water molecules, forming highly reactive platinum-based species.

These activated platinum species bind to the DNA in cancer cells, primarily forming covalent bonds with the purine bases (guanine and adenine), specifically at the N7 position of the purine rings. This binding results in the formation of DNA adducts, which because DNA cross-links, both within the same strand (intrastrand cross-links) and between complementary strands (interstrand cross-links). These cross-links prevent the DNA from unwinding and replicating, thereby blocking essential processes like transcription and replication.

Furthermore, the formation of these DNA adducts leads to the activation of various cellular stress pathways, including the p53-dependent apoptotic pathway. The inability of cancer cells to repair the DNA damage or cope with the induced cellular stress results in cell cycle arrest, particularly at the G1/S or G2/M checkpoint. Eventually, the accumulation of DNA damage triggers programmed cell death (apoptosis).

Therapeutic Efficacy

Platinum [$_{78}Pt^{195}$: $1s^2 2s^2 2p^6 3s^2 3p^6 4s^2 3d^{10} 4p^6 5s^2 4d^{10} 5p^6 4f^{14} 5d^9 6s^1$]-based drugs, such as cisplatin and carboplatin, have demonstrated significant therapeutic efficacy in a wide variety of cancers. Cisplatin, in particular, has been one of the most successful and commonly used chemotherapy agents since its discovery in the 1960s. Its use is often associated with high cure rates in cancers such as testicular cancer, where it has revolutionized treatment outcomes, leading to an overall survival rate of over 90%.

In ovarian cancer, carboplatin is frequently used due to its slightly more favorable toxicity profile compared to cisplatin. Carboplatin is less nephrotoxic and has a lower incidence of side effects, making it an attractive alternative in some settings. Nevertheless, both cisplatin and carboplatin are commonly used in combination with other agents, such as paclitaxel, to enhance therapeutic efficacy and improve overall survival rates.

The therapeutic success of platinum-based drugs is, however, limited by the development of resistance. Cancer cells can acquire resistance to cisplatin and carboplatin through several mechanisms, such as increased drug efflux, reduced drug uptake, enhanced DNA repair mechanisms, and changes in the apoptotic pathways. For example, the overexpression of certain proteins, like the multidrug resistance-associated protein (MRP), can reduce drug accumulation inside the cell, diminishing its effectiveness.[17]

Despite these challenges, ongoing research continues to explore strategies to overcome resistance, such as using platinum-based drugs in combination with novel agents or targeting resistance pathways. Furthermore, the development of second-generation platinum drugs, such as oxaliplatin, is aimed at reducing side effects and overcoming some of the resistance mechanisms associated with cisplatin.

Role of d-Block Elements in the Development of Antibacterial and Antifungal Agents, and Metal-Based Complexes in Targeted Drug Delivery

Transition metal complexes, particularly those involving silver, copper, platinum, and ruthenium, are proving to be valuable tools in the fight against bacterial and fungal infections, as well as in cancer therapy. Their antimicrobial properties, including their ability to generate reactive oxygen species and disrupt cellular structures, make them effective against resistant pathogens. Moreover, the ability to engineer metal-based complexes for targeted drug delivery has opened up new avenues for more precise and effective treatments. By exploiting the unique chemical properties of d-block elements, researchers are developing more selective and efficient therapeutic strategies, improving patient outcomes while minimizing side effects.

The development of antibiotics and antimicrobial drugs has been one of the most significant advancements in modern medicine. However, the emergence of antibiotic resistance has made it essential to explore alternative therapeutic strategies. One such promising approach involves the use of transition metals, particularly d-block elements like silver, copper, and other metal-based complexes, to combat bacterial, fungal infections, and even cancer. These metals have unique properties that make them effective in antimicrobial therapy, as well as in targeted drug delivery, enhancing the precision and efficacy of treatment.[18]

Role of d-Block Elements in Antibacterial and Antifungal Agents

Silver ($_{47}Ag^{108}$: $1s^2 2s^2 2p^6 3s^2 3p^6 4s^2 3d^{10} 4p^6 5s^1 4d^{10}$): Silver has been used for centuries as an antimicrobial agent. Its antibacterial properties are well-documented, and it has found applications in wound dressings, medical devices, and topical creams. Silver ions (Ag^+) exert antimicrobial activity by disrupting bacterial cell membranes, binding to sulfur and phosphorus groups in proteins and enzymes, and interfering with bacterial DNA replication. Silver nanoparticles (AgNPs) are particularly effective due to their large surface area, which increases their reactivity and allows them to interact with a wide range of microorganisms, including resistant strains of bacteria.

The antimicrobial mechanism of silver involves the generation of reactive oxygen species (ROS), which cause oxidative stress and damage to bacterial cell structures. Moreover, silver has been shown to inhibit bacterial biofilm formation, which is a major concern in chronic infections. The ability of silver to act against a broad spectrum of bacteria and fungi, including multi-drug-resistant strains, makes it an attractive candidate for future antimicrobial therapies.

Copper (Cu): Copper has also gained attention for its antimicrobial properties, especially in the form of copper-based compounds. Copper ions (Cu^{2+}) can disrupt bacterial cell membranes, leading to leakage of essential cellular components. Copper-based compounds, such as copper sulfate, have been used for their antifungal and antibacterial properties, particularly in agriculture. Copper ions can induce oxidative stress and damage to proteins, lipids, and DNA, which leads to cell death.

In addition to its broad-spectrum antimicrobial properties, copper has been studied for its potential in treating infections caused by fungi, such as Candida species, and bacteria like Escherichia coli and Staphylococcus aureus. The use of copper in antimicrobial treatments is increasingly being explored in the form of nanoparticles and copper-containing alloys, which exhibit enhanced effectiveness compared to bulk copper.

Metal-Based Complexes in Targeted Drug Delivery

Transition metal complexes are also playing an essential role in the development of targeted drug delivery systems. These complexes are made up of a metal ion coordinated to organic ligands, forming a stable structure that can be designed to carry drugs to specific sites in the body. The use of metal-based complexes offers several advantages in drug delivery, such as enhanced stability, controlled release, and the ability to target specific tissues or cells, including cancer cells.

Mechanism of Targeted Delivery: Metal-based complexes are often engineered to release drugs in response to specific triggers, such as changes in pH, temperature, or the presence of specific enzymes. For example, in the context of cancer treatment, tumour cells typically exhibit a more acidic microenvironment than normal tissues. Metal complexes can be designed to be stable at physiological pH but to release their drug payload in the acidic conditions found in tumors.

The metal ion in these complexes can also facilitate the formation of bonds with biological molecules such as proteins, nucleic acids, or lipids, allowing for selective targeting of diseased tissues. By attaching targeting ligands (e.g., antibodies or peptides) to the metal complex, the delivery system can be directed specifically to cancer cells or infected tissues, improving the therapeutic index and minimizing side effects.[19]

Examples of Metal-Based Complexes in Cancer Treatment

Several transition metal complexes have been developed for cancer treatment, showcasing the potential of metal-based drugs in targeted therapy.



Figure 2: d and f block elements.

Cisplatin (Pt-based complex): One of the most well-known metal-based drugs in cancer therapy is cisplatin, a platinum (II) complex. Cisplatin works by forming covalent bonds with DNA, causing cross-linking and disrupting DNA replication and transcription. This leads to cell death in rapidly dividing cancer cells. Cisplatin has been highly effective in treating cancers such as testicular, ovarian, and bladder cancer. However, its use is limited by its toxicity and the development of drug resistance. Researchers are now focusing on improving its targeting ability by combining it with other molecules or nanoparticles for more specific delivery to cancer cells.

Carboplatin (Pt-based complex): Carboplatin is a second-generation platinum drug with a structure similar to cisplatin but with fewer side effects, particularly less nephrotoxicity. It is used to treat a variety of cancers, including ovarian, lung, and head and neck cancers. Like cisplatin, carboplatin forms DNA adducts and induces cell cycle arrest and apoptosis, but its lower toxicity profile makes it a preferred option for some patients.

Ruthenium-based complexes: Ruthenium [$_{44}Ru^{101}$: $1s^2 2s^2 2p^6 3s^2 3p^6 4s^2 3d^{10} 4p^6 5^1 4d^7$], another transition metal, has emerged as a promising alternative to platinum in cancer therapy. Ruthenium-based complexes exhibit similar anticancer activity to cisplatin, but with potentially less toxicity. These complexes can be designed to target cancer cells specifically, either through the incorporation of targeting ligands or by taking advantage of the unique properties of cancer cell environments, such as acidic conditions.

Copper-based complexes: Copper complexes have been investigated for their ability to induce cell death in cancer cells through mechanisms involving oxidative stress and DNA damage. Copper-based complexes, often combined with targeting ligands, are being explored for their potential in treating cancers like leukemia and breast cancer. These complexes are thought to enhance the effectiveness of traditional chemotherapy by selectively delivering copper to cancerous tissues.[20]

Role of f-Block Elements in Pharmaceutical Medication: Lanthanides and Actinides in Medicine

The f-block elements, consisting of the lanthanides and actinides, play a significant yet often underappreciated role in pharmaceutical and medicinal chemistry. These elements, found in the bottom rows of the periodic table, have unique electronic configurations that make them particularly useful in a range of medical applications, from imaging and diagnostics to cancer therapy. Their properties—such as the ability to form stable complexes with organic molecules and their unique magnetic and radioactive characteristics—have led to their incorporation in various therapeutic and diagnostic agents.

Medicinal Uses of Lanthanides

Magnetic Resonance Imaging (MRI): One of the most prominent uses of lanthanides in medicine is in magnetic resonance imaging (MRI). Lanthanide ions, particularly gadolinium (Gd^{3+}), are used as contrast agents in MRI. Gadolinium [$_{64}Gd^{157}$: $1s^2 2s^2 2p^6 3s^2 3p^6 4s^2 3d^{10} 4p^6 5s^2 4d^{10} 5p^6 4f^7 5d^1 6s^2$]-based contrast agents enhance the contrast of images, allowing for more detailed and accurate imaging of internal tissues. Gadolinium ions have unique magnetic properties that improve the signal-to-noise ratio in MRI scans, making them invaluable in diagnostic imaging for detecting tumors, lesions, and vascular conditions.

Cancer Treatment: Lanthanide complexes have shown promise in cancer therapy, particularly in targeting cancer cells for localized treatment. For example, lanthanide compounds, such as those involving europium (Eu^{3+}) or terbium (Tb^{3+}), are being explored as potential therapeutic agents. These compounds can be designed to interact with specific biomolecules in cancer cells, facilitating the delivery of drugs or other therapeutic agents directly to the tumor site, reducing systemic toxicity and improving treatment efficacy.



Figure 3: Transition and Inner transition elements.

Radiotherapy: Lanthanides also play a role in radiation therapy, particularly for imaging and therapeutic purposes. Some lanthanide isotopes, such as samarium [$_{62}Sm^{150}$: $1s^2 2s^2 2p^6 3s^2 3p^6 4s^2 3d^{10} 4p^6 5s^2 4d^{10} 5p^6 4f^6 6s^2$]-153 and lutetium [$_{71}Lu^{175}$: $1s^2 2s^2 2p^6 3s^2 3p^6 4s^2 3d^{10} 4p^6 5s^2 4d^{10} 5p^6 4f^{14} 5d^1 6s^2$]-177, emit beta radiation, which can be used to target and destroy cancer cells. These radioactive isotopes are attached to specific molecules that bind selectively to tumour cells, providing targeted radiotherapy that minimizes damage to surrounding healthy tissues.[21]

Medicinal Uses of Actinides

Radioactive Therapy: The actinide series includes several radioactive elements, most notably uranium, thorium, radium, and actinium, which have found applications in cancer treatment. For example, actinium [$_{89}Ac^{227}$]-225 is being researched for targeted alpha-particle therapy. When linked to antibodies that target specific cancer cells, actinium-225 can deliver localized radiation to destroy tumour cells with minimal impact on healthy tissues. This type of treatment is highly effective in treating cancers that are difficult to treat with traditional methods, such as leukemia and prostate cancer.

Radium-223: Radium-223, a radioactive isotope of radium, has been developed as a treatment for metastatic bone cancer, particularly in cases of prostate cancer that have spread to the bones. Radium [$_{88}Ra^{226}$]-223 emits alpha radiation, which has a high energy but short range, making it effective in targeting bone metastases while minimizing damage to surrounding healthy tissues. This targeted radiotherapy has been shown to improve survival rates and reduce bone pain in patients with metastatic bone cancer.

Role of Lanthanides in Diagnostic and Imaging Techniques: Use of Gadolinium and Other Lanthanides in MRI Contrast Agents

Lanthanides, particularly gadolinium (Gd^{3+}), play a crucial role in modern diagnostic and imaging techniques, most notably in magnetic resonance imaging (MRI). MRI is a non-invasive imaging technique that provides high-resolution images of soft tissues in the body, making it invaluable for diagnosing a wide range of medical conditions, from neurological disorders to cancer. While MRI offers excellent soft tissue contrast, its resolution can be enhanced by the use of contrast agents, and lanthanide-based compounds, particularly gadolinium, are the primary agents used in this capacity.[22]

Gadolinium as a Contrast Agent

Gadolinium, a rare-earth metal in the lanthanide series, has unique magnetic properties that make it particularly effective as an MRI contrast agent. In its ionic form (Gd^{3+}), gadolinium has seven unpaired electrons, which contribute to its high magnetic susceptibility. This property enhances the signal in MRI scans, improving the contrast between different tissues. Gadolinium ions reduce the relaxation time of nearby water molecules in tissues, leading to increased signal intensity on T1-weighted MRI images. This effect allows doctors to distinguish between normal and abnormal tissues more easily, making it especially useful for imaging tumors, lesions, and blood vessels.

To ensure gadolinium is safe for use in patients, it is typically administered in the form of a chelated compound. Gadolinium chelates are stable and prevent free gadolinium ions from being released into the body, which could otherwise be toxic. Commonly used gadolinium-based contrast agents (GBCAs) include gadopentetate dimeglumine (Magnevist), gadodiamide (Omniscan), and gadobutrol (Gadavist).

Other Lanthanides in Imaging

While gadolinium is the most widely used lanthanide in MRI, other lanthanides such as europium [$_{63}Eu^{152}$: $1s^2 2s^2 2p^6 3s^2 3p^6 4s^2 3d^{10} 4p^6 5s^2 4d^{10} 5p^6 4f^7 6s^2$] ($Eu^{3+}$), terbium [$_{65}Tb^{159}$: $1s^2 2s^2 2p^6 3s^2 3p^6 4s^2 3d^{10} 4p^6 5s^2 4d^{10} 5p^6 4f^9 6s^2$] ($Tb^{3+}$), and dysprosium [$_{66}Dy^{162.5}$: $1s^2 2s^2 2p^6 3s^2 3p^6 4s^2 3d^{10} 4p^6 5s^2 4d^{10} 5p^6 4f^{10} 6s^2$] ($Dy^{3+}$) are also being explored for imaging purposes, although to a lesser extent. These lanthanides exhibit similar magnetic or luminescent properties that can be exploited in other diagnostic modalities, such as optical imaging or positron emission tomography (PET).

For example, europium and terbium complexes are used in luminescent probes for bioimaging, where their fluorescence properties can be harnessed for tracking specific biomolecules in biological systems. These lanthanides have narrow emission bands and high fluorescence quantum yields, which make them highly sensitive for detecting very low concentrations of target molecules.[23]

Radiopharmaceuticals: Applications of Radioactive Isotopes of Actinides in Cancer Treatment

Radiopharmaceuticals, which are radioactive compounds used in the diagnosis and treatment of diseases, have become increasingly important in modern medicine. Among these compounds, the radioactive isotopes of actinides—particularly uranium, thorium, radium, and actinium—are playing crucial roles in cancer treatment, offering new and targeted therapeutic strategies. Actinide-based radiopharmaceuticals leverage the unique properties of radioactivity, such as the emission of alpha or beta particles, to selectively target and treat cancer cells, minimizing damage to surrounding healthy tissues.

Actinide Isotopes in Radiotherapy

Actinide isotopes, such as uranium [$_{92}U^{238}$:$1s^2 2s^2 2p^6 3s^2 3p^6 4s^2 3d^{10} 4p^6 5s^2 4d^{10} 5p^6 4f^{14} 5d^{10} 6s^2 5f^3 6p^6 7s^2 3d^1$]-235, thorium [$_{90}Th^{232}$: $1s^2 2s^2 2p^6 3s^2 3p^6 4s^2 3d^{10} 4p^6 5s^2 4d^{10} 4f^{14} 5p^6 6s^2 5d^{10} 6p^6 7s^2 6d^2$]-227, radium [$_{88}Ra^{226}$: $1s^2 2s^2 2p^6 3s^2 3p^6 4s^2 3d^{10} 4p^6 5s^2 4d^{10} 5p^6 4f^{14} 5d^{10} 6s^2 7s^2 6p^6$]-223, and actinium [$_{89}Ac^{227}$: $1s^2 2s^2 2p^6 3s^2 3p^6 4s^2 3d^{10} 4p^6 5s^2 4d^{10} 5p^6 4f^{14} 5d^{10} 6s^2 7s^2 6p^6 6d^1$]-225, are used in targeted radiotherapy, a form of treatment that uses radioactive materials to selectively irradiate cancer cells. These isotopes emit high-energy particles (alpha and beta radiation) that can penetrate the cancerous tissue and destroy the malignant cells.

Radium-223 (Ra-223): One of the most well-known applications of an actinide isotope in cancer treatment is the use of radium-223 in treating metastatic bone cancer, particularly in prostate cancer. Radium-223 is a potent alpha emitter, meaning it produces high-energy alpha particles that travel only short distances in the body, typically around 100 micrometers. This short range makes it ideal for targeting bone metastases, as it delivers localized radiation directly to the tumor while minimizing exposure to surrounding healthy tissues.

Radium-223 mimics calcium and is selectively incorporated into the bone matrix, where it is used by bone cells. When it decays, it emits alpha particles that cause double-strand breaks in DNA, leading to cell death in the cancerous bone tissues. This targeted approach has been shown to reduce pain, improve survival rates, and enhance the quality of life in patients with metastatic prostate cancer.

Actinium-225 (Ac-225): Actinium-225 is another actinide isotope that has shown promise in targeted cancer therapy. Ac-225 emits high-energy alpha particles that are highly effective in killing cancer cells due to their ability to cause significant DNA damage. One of the advantages of alpha radiation is that it has a high linear energy transfer (LET), meaning it deposits more energy over a short distance, making it highly effective in killing cancer cells while minimizing damage to surrounding tissues.

Ac-225 is often linked to monoclonal antibodies or peptides that specifically target cancer cells, allowing for the delivery of the radioactive isotope directly to the tumour. This form of targeted alpha-particle therapy (TAT) has been studied in a variety of cancers, including leukemia, prostate cancer, and non-Hodgkin lymphoma. The specificity of Ac-225-based radiopharmaceuticals ensures that radiation is delivered precisely to the cancer cells, improving treatment efficacy while minimizing side effects.[24]

Thorium-227 (Th-227): Thorium-227 is another actinide isotope that has been researched for its potential in cancer treatment. Similar to radium-223, thorium-227 is an alpha emitter, but it is often used in conjugation with antibodies that specifically target cancer cells. Once attached to the tumour site, thorium-227 emits alpha particles that cause localized DNA damage, leading to tumour cell death.

One of the major advantages of thorium-227 is its ability to deliver highly potent radiation directly to cancer cells, which is particularly useful in treating cancers that are difficult to reach with conventional treatments. Thorium-227 is being explored for its application in cancers such as ovarian cancer and other solid tumors, where its targeted delivery can overcome some of the limitations of traditional therapies.

The f-Block Elements in Drug Formulations: Potential Uses in Drug Stabilization and Formulation

The f-block elements, consisting of the lanthanides and actinides, have gained increasing attention in drug formulations due to their unique chemical properties, such as high stability, ability to form strong coordination complexes, and magnetic or radioactive characteristics. These properties make them ideal candidates for enhancing the stability and efficacy of pharmaceutical drugs, as well as for creating targeted drug delivery systems. Here's a look at how f-block elements can be used in drug stabilization and formulation.

Stabilization of Drugs

One of the key challenges in drug formulation is ensuring the stability of pharmaceutical compounds. Some drugs are prone to degradation due to factors such as oxidation, hydrolysis, or light exposure. Lanthanides, particularly those like lanthanum, cerium, and europium, are known for their ability to stabilize drugs by forming coordination complexes with active pharmaceutical ingredients (APIs). By binding with these elements, drugs can be protected from degradation processes. For example, lanthanum salts are sometimes used in the stabilization of certain proteins or peptides, preventing them from denaturing or losing their biological activity.

Additionally, lanthanides such as cerium have been investigated for their antioxidant properties, which can protect drugs from oxidative stress, a major factor in the degradation of sensitive molecules, especially in formulations containing biologics. Cerium oxide nanoparticles have shown promise as antioxidant agents that can help prolong the shelf-life of pharmaceutical products, particularly those sensitive to oxidation.

Drug Delivery Systems

The f-block elements are particularly useful in the development of targeted drug delivery systems. Their ability to form stable complexes with various ligands allows for the design of sophisticated drug carriers that can deliver therapeutic agents precisely to their intended target. For example, gadolinium (Gd) and europium [$_{63}Eu^{152}$] (Eu) are often used in the formulation of magnetic or luminescent nanoparticles. These nanoparticles can be engineered to carry drugs to specific tissues or cells, offering targeted therapy with minimal side effects.[25]

Gadolinium-based nanoparticles, in particular, are being used for magnetic targeting in chemotherapy, where the particles are attracted to tumour sites by an external magnetic field. Similarly, lanthanide complexes with fluorescent properties are used in diagnostic imaging and monitoring the distribution of drugs within the body, allowing for real-time tracking of drug delivery and ensuring that therapeutic agents reach their target.

Radiopharmaceuticals

Actinides such as radium and actinium are used in radiopharmaceuticals, where their radioactive properties are harnessed to target specific cancer cells. In these applications, f-block elements help enhance the effectiveness of drug formulations by offering a method of delivering high-energy radiation directly to the tumour site, thus minimizing systemic toxicity. These targeted radiotherapy techniques rely on the strong coordination chemistry of actinides with biomolecules, ensuring that radiation is released precisely at the tumour, maximizing the therapeutic effect.

Mechanisms of Action of d and f-Block Elements in Medications

The transition (d-block) and inner transition (f-block) elements possess distinct chemical properties that make them highly effective in a range of therapeutic applications. These elements, due to their unique electronic configurations and ability to coordinate with various ligands, play significant roles in modulating biological systems. They can interact with biomolecules such as proteins, DNA, and enzymes, exerting therapeutic effects through mechanisms such as binding, redox reactions, and modulation of cellular pathways. Below, we will explore the various mechanisms of action of these metal ions in medications, particularly in their interactions with biological molecules and their effects on health.

Binding and Coordination with Biomolecules

Both d- and f-block elements have a remarkable ability to form stable coordination complexes with biomolecules. This is due to their flexible oxidation states and their tendency to coordinate with ligands (atoms, molecules, or ions that can donate electrons to the metal center). In the context of medications, these metal ions often interact with the biomolecules that play critical roles in cellular processes.

For example, platinum-based drugs, such as cisplatin and carboplatin, are d-block elements that bind to DNA. The platinum ion, upon entering the cell, reacts with the purine bases in the DNA, particularly guanine. This coordination leads to the formation of DNA cross-links, inhibiting DNA replication and transcription. The cross-links prevent cell division, causing apoptosis (cell death) in rapidly dividing cancer cells, making cisplatin a powerful anticancer drug.

In another example, lanthanides such as gadolinium and europium are frequently used in diagnostic imaging (MRI and PET scans) due to their ability to coordinate with chelating agents. These lanthanides bind to biomolecules in the body, enhancing imaging techniques by improving the contrast and making tissue structures more visible. Such coordination allows the imaging agent to circulate through the body and localize to specific tissues.[26]

Interaction with Proteins, DNA, and Other Biological Molecules

The interaction of metal ions with proteins, nucleic acids, and other biological molecules is a key mechanism of action in medicinal chemistry. Metal ions influence protein structure and function by coordinating with amino acid residues (such as cysteine, histidine, and glutamate) within the protein's active sites. For example, in metalloenzymes, metal ions are often central to the enzyme's active site and essential for its catalytic activity.

For example, in the case of certain anticancer therapies, platinum compounds (like cisplatin) bind directly to DNA, distorting its double-helix structure. This distortion prevents DNA from being properly replicated or transcribed, which leads to cell death. On the other hand, some lanthanide complexes, like terbium (Tb) and europium (Eu), exhibit fluorescence properties when bound to biological molecules like proteins or peptides. This ability is exploited in research for tracing protein-protein interactions or mapping the distribution of specific biomolecules in tissues, thereby aiding in diagnostics and therapeutic monitoring.

In certain cases, actinide compounds, such as uranium, may interact with biological molecules, although these are more often studied for their toxicity and their radioactive properties rather than for therapeutic use. The radioactive properties of these actinides are harnessed in radiopharmaceuticals for targeted cancer treatment. These compounds deliver localized radiation to cancer cells, often using monoclonal antibodies as delivery vehicles.

Modulation of Biological Pathways

The d- and f-block elements can influence multiple biological pathways by interacting with enzymes, receptors, and ion channels. Many enzymes, particularly those involved in cellular metabolism, require metal ions for their activation and function. For example, zinc and copper, which are d-block elements, play crucial roles in enzymes such as superoxide dismutase (SOD) and cytochrome c oxidase, which are involved in cellular respiration and defense against oxidative stress. The modulation of biological pathways can have therapeutic effects, particularly in the treatment of diseases like cancer, neurodegenerative disorders, and cardiovascular conditions. For instance, cisplatin, a platinum-based anticancer drug, modulates apoptotic pathways by binding to DNA and activating tumour suppressor genes or interfering with cell cycle regulation. Similarly, other platinum complexes are under investigation for their ability to interact with various signaling pathways in cancer cells to enhance the therapeutic outcome.

Furthermore, metals like iron and copper are essential for oxygen transport and electron transfer in biological systems. These elements are often part of heme groups in haemoglobin and myoglobin or involved in mitochondrial respiration. By influencing these pathways, transition metals can affect tissue oxygenation and energy production, which is important for therapies targeting metabolic disorders.

Impact of Metal Ions on Enzymes, Receptors, and Cellular Signaling

The d-block and f-block metals can have a profound effect on enzyme activity, receptor binding, and cellular signaling. Many biological enzymes, including those involved in DNA repair, antioxidant defense, and metabolism, are metalloenzymes that require metal ions for their catalytic activity. The binding of metal ions to enzymes can either activate or inhibit their activity, leading to changes in cellular processes. For instance, gold, a d-block metal, has been used in the treatment of rheumatoid arthritis. Gold ions interfere with immune system signaling by inhibiting the activity of enzymes involved in inflammation. Similarly, copper is crucial for the function of cytochrome c oxidase, a key enzyme in cellular respiration, and it has been implicated in neurodegenerative diseases, such as Alzheimer's disease, where copper dysregulation is thought to contribute to neuronal damage.

Transition metals can also modulate receptor activity. For example, zinc ions are known to influence the binding and activation of certain receptors in the brain, such as NMDA receptors, which play a role in memory and learning. Manipulating these receptors through metal-based drugs may offer therapeutic benefits for neurological disorders.

Redox Reactions and Catalysis

Redox reactions, which involve the transfer of electrons between molecules, are fundamental to many biological processes. Transition and inner transition metals are highly effective in catalysing redox reactions due to their ability to change oxidation states. These metals can either donate or accept electrons, facilitating various biochemical processes, including detoxification, energy production, and DNA repair.

For example, platinum drugs like cisplatin and carboplatin can act as redox agents, participating in electron transfer reactions that lead to the formation of highly reactive oxygen species (ROS). These ROS can cause DNA damage and cellular stress, ultimately leading to apoptosis. In this way, the redox properties of platinum-based drugs contribute to their anticancer activity.

Additionally, metals such as iron, copper, and manganese are essential cofactors in enzymes involved in redox processes. These enzymes help maintain cellular homeostasis by neutralizing reactive oxygen species and reducing oxidative stress. The therapeutic potential of redox-active metal ions extends to treating oxidative stress-related diseases, such as Parkinson's disease, where redox-active compounds are being explored as potential therapeutic agents.[27]

How the Redox Properties of d and f Block Elements Enhance Therapeutic Effects

The redox properties of d- and f-block elements significantly enhance the therapeutic effects of many drugs. These metals can undergo reversible oxidation and reduction reactions, making them ideal for use in catalytic processes and in the activation of therapeutic agents. For example, the redox properties of copper, iron, and manganese are harnessed in the development of drugs aimed at treating oxidative stress-related conditions, such as neurodegenerative diseases and cardiovascular disorders.

In anticancer therapy, redox-active metals like platinum and ruthenium have been used to generate reactive species that damage cancer cells. The ability of platinum to create highly reactive intermediates through redox reactions enhances the cytotoxicity of these drugs, targeting cancer cells more effectively. Additionally, the redox activity of these metals allows them to activate prodrugs, which remain inactive until they encounter the specific biological environment of the target site, reducing side effects and increasing the precision of therapy.

Challenges and Considerations in the Use of d- and f-Block Elements in Medicine

The use of d- and f-block elements in medicine has revolutionized various therapeutic approaches, including anticancer treatment, diagnostic imaging, and targeted drug delivery. However, as with any therapeutic modality, the application of metal-based drugs raises significant challenges and considerations, particularly related to toxicity, bioavailability, pharmacokinetics, and environmental impact. Below, we will explore the key issues associated with the use of transition (d-block) and inner transition (f-block) metals in pharmaceuticals, focusing on concerns such as toxicity, pharmacological challenges, and environmental sustainability.

Toxicity and Safety Concerns

One of the most significant challenges when using d- and f-block elements in medicine is the potential for toxicity. Many metals, especially those in the actinide series (such as uranium, thorium, and radium), and even some transition metals like platinum, can pose substantial health risks when misused or administered improperly. These risks are typically associated with their ability to interact with cellular components, often causing irreversible damage.

For example, cisplatin, a platinum-based chemotherapy drug, is effective in treating various cancers but comes with significant toxicity, particularly to the kidneys (nephrotoxicity). Cisplatin's mechanism of action involves binding to DNA, causing cross-links and strand breaks that trigger apoptosis in rapidly dividing cancer cells. However, platinum ions can also interact with healthy tissues, especially the kidneys, leading to severe side effects. Furthermore, platinum compounds may accumulate in the body over time, posing a risk of long-term toxicity.

Other metals, such as radium-223, used in the treatment of metastatic bone cancer, are radioactive, and while they provide targeted radiation to treat bone metastases, there is the risk of radiation damage to surrounding tissues if not carefully monitored. Radioactive metals, such as those in the actinide series, can also pose a risk of carcinogenicity and genetic mutations, adding another layer of concern regarding their safety and application in medicine.

Potential Risks of Overdose and Side Effects of Metal-Based Drugs

Overdose and the subsequent side effects of metal-based drugs are major concerns in their clinical use. Metals like platinum and gold, which are used in chemotherapy and rheumatoid arthritis treatments, respectively, can be toxic in high concentrations. In the case of cisplatin, overdose can lead to acute renal failure, bone marrow suppression, and hearing loss, among other serious side effects.

Similarly, gold-based drugs such as auranofin are used in the treatment of rheumatoid arthritis, but they can cause a range of side effects including gastrointestinal disturbances, rashes, and even renal damage. Overdosing with actinide elements, especially radioactive compounds, can also result in radiation poisoning and organ damage, as these elements release ionizing radiation.

Toxicity is also influenced by the chemical form of the metal. For example, platinum compounds that are highly reactive can cause greater systemic toxicity if they are not well-targeted to cancer cells. Therefore, a crucial aspect of the therapeutic use of these metals involves minimizing exposure to non-target tissues and ensuring precise delivery to the intended site of action.[28]

Toxicological Studies and Safety Regulations in Metal-Based Medications

The use of metal-based drugs necessitates comprehensive toxicological studies to ensure safety and minimize adverse effects. Safety regulations in the use of metal-based medications are stringent, as metals can accumulate in the body, sometimes leading to delayed toxicity. Before a metal-based drug can be approved for clinical use, it undergoes a range of preclinical and clinical trials to assess its safety profile, including acute toxicity, chronic toxicity, genotoxicity, and carcinogenicity studies.

For example, platinum-based drugs like cisplatin undergo rigorous testing to evaluate their nephrotoxicity and ototoxicity (hearing loss), which are well-documented side effects. The regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), require extensive toxicological studies to ensure the safety of any metal-based drug before its market approval.

Additionally, safety protocols must be in place during the manufacturing, handling, and administration of metal-based drugs, especially for those involving radioactive materials. This includes the use of specialized containment facilities for radiopharmaceuticals, as well as proper disposal techniques to minimize exposure to radioactive isotopes.

Bioavailability and Pharmacokinetics

Bioavailability and pharmacokinetics are crucial factors that determine the efficacy and safety of metal-based drugs. Bioavailability refers to the proportion of a drug that enters the bloodstream and reaches the target site in the body, while pharmacokinetics involves the study of drug absorption, distribution, metabolism, and excretion (ADME).

The absorption of metal ions can be influenced by various factors, including the chemical form of the metal, its charge, and its ability to form stable complexes with other molecules in the body. For instance, platinum compounds like cisplatin are generally administered intravenously, as they have limited oral bioavailability due to poor absorption in the gastrointestinal tract.

The distribution of metal ions is another critical factor. Once administered, the metal ion must be able to reach its target tissue, whether it is a cancerous tumor, an inflamed joint, or another site. The presence of biological molecules such as serum proteins can influence the distribution of metal-based drugs, as these metals often form complexes with proteins, altering their distribution and clearance.

The metabolism and excretion of metal ions are also important. Many metals, including platinum, tend to accumulate in organs such as the liver and kidneys, where they can exert toxic effects. For example, cisplatin is known to be metabolized by the liver, and its metabolites can cause nephrotoxicity. Excretion often occurs through the kidneys, which is why renal function must be closely monitored during treatment with metal-based drugs.

Factors Affecting the Absorption and Distribution of Metal Ions in the Body

The absorption and distribution of metal ions in the body are governed by multiple physiological factors. Metal ions must overcome biological barriers such as the gastrointestinal lining, blood-brain barrier, and cell membranes to reach their target site. Chelating agents often play an essential role in improving the bioavailability of metals, as they bind to metal ions, preventing their interaction with unwanted molecules while facilitating their transport across biological membranes.

Ion transporters and channels in the body regulate the movement of metal ions. For example, copper and zinc are actively transported into cells via specific transporters, while metals like platinum are taken up by cells through endocytosis. Once inside the cells, the metal ions must be properly distributed to reach their target organs or tissues. For example, radium-223, used for metastatic bone cancer, preferentially accumulates in bone tissues, exploiting the natural calcium uptake mechanism. Factors such as pH and the presence of other metals can also affect absorption. In the case of platinum-based drugs, the acidic environment in tumors helps enhance their uptake, as platinum complexes are more stable in lower pH environments.[29]

Environmental Impact and Sustainability

The environmental impact of using d- and f-block elements in medicines is a significant concern, especially given the extraction and disposal processes associated with these metals. The mining of metals such as platinum, uranium, and other precious and radioactive metals can be environmentally harmful, involving energy-intensive processes that lead to habitat destruction, pollution, and greenhouse gas emissions.

For example, platinum mining, which is primarily concentrated in South Africa, is an energy-intensive process that can lead to soil and water contamination due to the release of toxic byproducts. Similarly, the mining of uranium for nuclear medicine or radiopharmaceuticals raises concerns about radioactive waste and the contamination of ecosystems.

The disposal of metal-based drugs also presents challenges. After a metal-based drug is used in therapy, any remaining drug or its byproducts must be carefully managed to avoid environmental contamination. Radioactive metals, such as those used in radiopharmaceuticals, require special disposal methods to prevent radiation exposure to the environment and humans.

In addition, the sustainability of metal-based pharmaceuticals is an area of increasing focus. Researchers are exploring ways to recycle and reuse metals, such as platinum, and to develop more environmentally friendly methods for extracting these metals. Furthermore, efforts to reduce the environmental impact of radiopharmaceuticals are ongoing, with advancements in the safe disposal and recycling of radioactive isotopes.

Future Directions and Research in d- and f-Block Elements in Pharmaceutical Medicine

The use of d- and f-block elements in pharmaceutical medicine has led to groundbreaking advances in cancer treatment, diagnostic imaging, and the management of various diseases. However, as with any evolving field, there is considerable ongoing research aimed at improving the effectiveness, reducing the toxicity, and expanding the applications of metal-based drugs. Future directions in the use of these elements will revolve around the design of more efficient metal complexes, the integration of personalized medicine, and the application of emerging technologies such as nanotechnology and biomolecular engineering. Below are key areas where research is making strides in the development of metal-based therapeutics.

Advances in Metal-Based Drug Design

A significant area of future research in the use of d- and f-block elements in pharmaceuticals is the development of more efficient, less toxic metal complexes. While platinum-based drugs like cisplatin have revolutionized cancer treatment, their effectiveness is often overshadowed by significant toxicities, such as nephrotoxicity, ototoxicity, and neurotoxicity. To overcome these challenges, researchers are focusing on designing novel metal complexes that are more selective in targeting cancer cells while minimizing side effects.

Recent developments in the design of metal-based anticancer drugs have focused on using alternative transition metals such as ruthenium, copper, and gold, which exhibit promising antitumor activity with fewer side effects compared to platinum. For instance, ruthenium complexes have been shown to interact with DNA in a manner similar to cisplatin but with less damage to healthy tissues. Ruthenium compounds are also more biocompatible and exhibit favorable pharmacokinetics, making them an attractive alternative in cancer therapy.

Another promising approach is the use of metal-ligand coordination to improve the specificity and stability of metal-based drugs. The design of biocompatible ligands that can selectively bind to cancer-specific biomarkers or tissues has gained attention. For example, targeted delivery systems using antibodies, peptides, or other targeting agents to guide metal-based drugs to tumour cells are being developed. These strategies help reduce the systemic exposure of the drug to healthy cells, enhancing the therapeutic index and minimizing side effects.

Moreover, the development of bimetallic complexes involving two different metal ions is a growing area of interest. These complexes can exhibit synergistic effects, where the combined properties of the metals enhance the drug's efficacy or overcome drug resistance mechanisms in cancer cells. The ongoing exploration of these multi-metal systems holds great promise for the future of metal-based drug design.

Personalized Medicine and Metal-Based Therapeutics

One of the most exciting frontiers in medicine is the concept of personalized medicine, which tailors medical treatment to the individual characteristics of each patient. Personalized medicine has the potential to optimize the therapeutic efficacy of metal-based drugs by considering factors such as genetic makeup, metabolic profile, and individual response to treatment. Research is increasingly focused on understanding how genetic and metabolic differences affect the response to metal-based drugs, thereby paving the way for more precise and effective treatments.

Genetic factors can significantly influence how a patient metabolizes and responds to metal-based drugs. For example, platinum compounds are known to interact with DNA, but variations in the patient's DNA repair mechanisms or tumor microenvironment can influence how effectively these drugs work. Some patients may have genetic mutations that make them more sensitive to platinum-based drugs, while others may develop resistance due to the overexpression of drug efflux pumps or DNA repair pathways.

By identifying these genetic predispositions, clinicians can tailor chemotherapy regimens to suit the individual's genetic profile, ensuring better outcomes and reducing adverse side effects. For instance, pharmacogenomic testing can predict which patients are more likely to benefit from specific platinum compounds or identify those who may experience severe toxicity. Personalized medicine could also extend to the selection of metal-based drugs based on a patient’s unique metabolic pathways or biomarkers expressed in their tumors. Personalized approaches might not only improve the therapeutic efficacy of existing drugs but also guide the development of future treatments that are tailored to an individual’s specific needs.

Furthermore, metal-based immunotherapy is an emerging area of personalized medicine, where metals are used to enhance the body’s immune response against cancer cells. For instance, gold nanoparticles are being studied for their ability to activate immune cells, while simultaneously delivering chemotherapeutic agents directly to the tumour. By combining metal-based drugs with immunotherapies, personalized treatments could potentially offer a more holistic approach to cancer treatment, maximizing the effects while minimizing toxicity.[30]

Emerging Technologies

The integration of emerging technologies will play a crucial role in enhancing the delivery and efficacy of metal-based drugs. Two particularly promising technologies are nanotechnology and biomolecular engineering, which are being explored for their potential to revolutionize the way metal-based drugs are administered and utilized in medical treatments.[31]

Nanotechnology: Nanotechnology involves the manipulation of matter at the nanoscale (typically 1-100 nanometers), and it has great potential for improving the delivery of metal-based drugs. Nanoparticles made from gold, silver, or other metals can be engineered to carry and deliver drugs directly to the site of action, such as tumors or infected tissues. Metal nanoparticles are advantageous because they can be functionalized with ligands (such as antibodies or peptides) that allow for targeted delivery, reducing off-target effects and improving drug bioavailability.

For example, gold nanoparticles have shown great promise in enhancing the targeting of cancer cells. These nanoparticles can be loaded with anticancer drugs and directed to tumour sites via specific ligands or antibodies that recognize tumour-specific markers. Additionally, gold nanoparticles can also be used in photothermal therapy, where they absorb light and convert it into heat, selectively destroying cancer cells while minimizing damage to surrounding tissues.

Nanocarriers can also be designed to overcome the limitations of traditional metal-based drugs, such as poor solubility, rapid clearance from the body, or toxicity. By encapsulating metal-based drugs in nanoparticles, researchers can create drug delivery systems that provide sustained release of the drug over time, improving therapeutic outcomes.[32]

Biomolecular Engineering: Advances in biomolecular engineering are also poised to enhance the precision and effectiveness of metal-based therapeutics. Engineered proteins and peptides can be designed to bind selectively to metal ions, improving drug stability and delivery. For example, metal-binding peptides could be used to direct metal ions to specific tissues or cells, enhancing the targeting of metal-based drugs.

Additionally, enzyme-based drug delivery systems are being investigated. Some enzymes can catalyze the release of metal-based drugs at specific sites in the body. For instance, researchers are exploring the use of metal-releasing enzymes that can activate metal-based drugs directly at tumour sites, providing a more localized therapeutic effect. This could reduce systemic toxicity and improve the drug's therapeutic index.

Biomolecular engineering could also facilitate the development of smart drug delivery systems that respond to environmental stimuli (e.g., pH, temperature, or enzyme activity) to release metal-based drugs precisely when and where they are needed. This level of control is particularly useful in cancer therapy, where precise targeting of tumour cells is critical to maximizing therapeutic effects while minimizing damage to healthy tissues.[33]

CONCLUSION

The role of d and f block elements in pharmaceutical medications has been a transformative advancement in the field of medicine. These transition and inner transition metals, which include platinum, gold, ruthenium, gadolinium, uranium, and others, have provided a wealth of therapeutic applications, particularly in areas such as cancer treatment, diagnostic imaging, and the development of novel drug delivery systems. Their unique chemical properties, including their ability to form stable coordination complexes, redox activity, and interactions with biological molecules, have enabled significant progress in both chemotherapy and targeted therapies. These elements continue to shape the landscape of modern medicine, offering powerful tools for treating a variety of diseases while presenting new opportunities for therapeutic innovation.

The significance of d- and f-block elements in pharmaceutical preparations cannot be overstated. These elements have led to the development of metal-based anticancer drugs like cisplatin, which revolutionized chemotherapy by providing an effective treatment for various cancers, particularly ovarian, lung, and testicular cancers. Platinum-based compounds, as well as drugs utilizing ruthenium, copper, and gold, have also demonstrated potential as alternative therapies with less toxicity compared to traditional chemotherapy agents. Additionally, the use of radioactive isotopes from the actinide series, such as radium-223, in the treatment of metastatic cancer has opened new avenues for targeted therapies that minimize damage to healthy tissues. The role of gadolinium in MRI contrast agents highlights how lanthanides, with their unique electronic configurations, contribute to the development of cutting-edge diagnostic techniques.

Moreover, the ability of metal-based complexes to engage in bio-coordination, interacting with proteins, enzymes, DNA, and other biological molecules, has enabled the development of targeted drug delivery systems. These complexes can be engineered for precise action, reducing off-target toxicity and improving the overall therapeutic index of drugs. By leveraging the unique properties of metals like gold nanoparticles and copper complexes, researchers have advanced nanomedicine and personalized medicine, which promise more effective, individualized treatments.

While significant strides have been made, the potential of d- and f-block elements in pharmaceuticals is far from fully realized. There is a clear need for continued innovation in the design and development of metal-based medications. Although compounds like cisplatin are widely used, they still carry significant side effects, such as nephrotoxicity and ototoxicity. Therefore, the quest for new, less toxic metal complexes remains critical. Future research should focus on more selective targeting mechanisms that would enhance the efficacy of metal-based drugs while minimizing systemic toxicity. This could involve the development of smarter drug delivery systems, such as nanoparticles or biomolecular engineered complexes, which release drugs in response to specific tumour microenvironments or genetic profiles.

Additionally, the integration of personalized medicine will allow clinicians to tailor treatments based on a patient's unique genetic and metabolic characteristics. This approach could not only improve treatment efficacy but also reduce adverse reactions by selecting the right metal-based drug for each individual. As we understand more about drug resistance mechanisms, such as those that limit the effectiveness of platinum-based drugs, it will be essential to design therapies that can overcome these barriers.

Finally, sustainability remains a vital consideration in the use of metal-based drugs. The mining and disposal of metals, particularly rare and radioactive elements, can pose significant environmental risks. As such, continued efforts to make metal-based drug development more environmentally friendly and economically sustainable will be essential to ensure the longevity and responsible use of these powerful therapeutic tools.

In conclusion, the d- and f-block elements have already proven themselves as valuable assets in the development of pharmaceutical medications. Their unique properties enable them to function as powerful therapeutic agents and diagnostic tools. However, to fully realize their potential, continued innovation is essential. As research progresses, metal-based medications will likely become more targeted, efficient, and safer, allowing for the development of personalized, highly effective treatments that can address a broad spectrum of diseases. Moreover, by advancing the technologies surrounding drug delivery, toxicity reduction, and sustainability, these metals will continue to play a pioneering role in shaping the future of medicine. The future of pharmaceutical therapy lies in the careful and intelligent harnessing of these elements, providing hope for more precise, effective, and accessible medical solutions.

REFERENCES

1. Sharma P, Singh A, Soni S. Role of transition metals in drug development. J Pharm Res., 2020; 13(3): 435-444.
2. Kumar A, Choudhury R, Gupta V. Lanthanides and their pharmaceutical applications: A review. J Inorg Biochem., 2018; 179: 32-39.
3. Zhao Y, Li X, Zhang Z. The therapeutic potential of f-block elements in modern pharmaceuticals. Coord Chem Rev., 2022; 453: 213-222.
4. Ghosh S, Banerjee S. d-Block elements and their impact on the formulation of therapeutic drugs. Chem Pharm Bull., 2019; 67(6): 494-502.
5. Tanaka H, Hasegawa T, Nakayama K. Medicinal applications of rare earth metals. J Med Chem., 2016; 59(7): 2020-2033.
6. Lee J, Zhao S. Biocompatibility of transition metal complexes as drug delivery agents. J Pharm Sci., 2017; 106(2): 387-396.
7. Choudhury R, Patel H, Mehta N. Synthesis and pharmaceutical properties of f-block element complexes. J Inorg Chem., 2020; 54(5): 512-520.
8. Hwang Y, Lee S, Kim S. Chemical properties of the d-block and their importance in drug therapy. J Med Chem., 2017; 60(11): 4312-4325.
9. Bhandari S, Sharma D. Transition metal ions in medicinal chemistry: Perspectives and applications. Eur J Pharm Sci., 2021; 25(4): 145-156.
10. Asher V, Gupta R, Kaur R. New trends in the application of transition metal complexes in anti-cancer therapies. Oncol Lett., 2019; 18(2): 1441-1450.
11. Shah H, Kumar S. Pharmacological efficacy of platinum-based d-block metal complexes in chemotherapy. J Drug Target., 2018; 26(1): 1-10.
12. Singh M, Patel R. Rare earth metals in drug development: A new approach. Adv Pharmacol., 2021; 72: 108-117.
13. Lee A, Park J, Kim Y. The role of lanthanides in therapeutic interventions. Eur J Inorg Chem., 2020; 2020(8): 1121-1130.
14. Pandey M, Singh R. Metal ion complexes as novel therapeutic agents. J Pharm Biomed Anal., 2019; 168: 26-32.
15. Hong Z, Zhang H, Li M. Transition metal complexes in drug design: Applications and future directions. Chem Soc Rev., 2018; 47(11): 4070-4084.
16. Zhang Y, Liu S, Sun L. Bioactive f-block metal complexes in cancer treatment. Coord Chem Rev., 2020; 417: 213-224.
17. Mehta N, Kumar S. Medicinal applications of d- and f-block elements: A review of recent developments. J Inorg Chem., 2019; 56(12): 872-888.
18. Gupta S, Kumar V, Soni M. Therapeutic implications of transition metals in disease treatment. Chem Med Chem., 2020; 15(6): 451-460.
19. Kumar J, Choudhary P. Pharmaceutical formulations with lanthanide-based complexes. Chem Pharm Bull., 2021; 69(5): 389-395.
20. Singh H, Kumar M. Transition metal compounds as potential anti-inflammatory agents. Med Chem., 2019; 62(5): 1005-1015.
21. Patel V, Gupta A. D-block metal complexes in cancer treatment: A promising approach. Anti-Cancer Agents Med Chem., 2018; 18(2): 209-220.
22. Sharma R, Yadav R, Khan F. Rare earth metal drugs in neurology: Exploring novel applications. Chem Bio Chem., 2022; 23(3): 405-415.
23. Taylor S, Chan S. The use of f-block elements in drug development. Coord Chem Rev., 2019; 436: 161-170.
24. Banerjee D, Gupta N. Transition metal ion interactions in pharmaceutical design. J Chem Biol., 2018; 27(3): 350-357.
25. Patel S, Yadav P. Synthesis and biological activity of metal-ligand complexes in pharmaceutical applications. Biometals., 2017; 30(2): 171-182.

26. Kulkarni R, Singh S. Advances in pharmaceutical applications of d- and f-block metal complexes. Inorg Chem Commun., 2021; 121: 108073.
27. Ghosh A, Patel K. The potential of rare earth elements in therapeutic interventions. Drug Dev Res., 2020; 81(5): 531-541.
28. Kumar S, Mehta G. Applications of lanthanides in drug delivery systems. Mater Sci Eng C., 2020; 108: 110378.
29. Kumar R, Deshmukh S. Transition metal complexes as antitumor agents: A review. Metal-Based Drugs., 2021; 2021: 973012.
30. Soni P, Gupta R. Bioactivity of f-block element-based drugs in pharmaceutical applications. J Biol Inorg Chem., 2020; 25(7): 953-965.
31. Lee C, Wang L, Lee T. Medicinal properties of transition metal complexes: A review. Inorg Chem., 2018; 57(5): 2456-2464.
32. Roy M, Das S. Transition metal complexes in drug therapy: Synthesis, characterization, and biological evaluation. Chem Biol Drug Des., 2019; 94(1): 9-18.
33. De A, Roy N C, Goswami S, Sarkar A, Guchait P, Brahma S and Sen D J; Nuclear medicine as molecular imaging probes radionucleotide in radiopharmaceuticals in scintigraphy of diagnostic aids: World Journal of Advance Healthcare Research, 2024; 8(11): 216-236.